title: Developmentally informed pharmacotherapy for child and adolescent depressive disorders.
abstract: This article reviews evidence-based pharmacotherapy for children and adolescents with depression. Several randomized controlled trials (RCTs) support the use of fluoxetine for the treatment of childhood and adolescent depression as well as escitalopram in the treatment of adolescent depression. To date, one RCT has demonstrated the effectiveness of sertraline or citalopram for the treatment of major depressive disorder in youth. Only a small number of RCTs for depression have included children, and none of these trials were adequately powered to detect differences in the efficacy of medication between children and adolescents.
authors.affiliation: Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 100 North Bellefield Avenue, Pittsburgh, PA 15213, USA. sakolskydj@upmc.edu
authors.forename: Dara
authors.initials: D
authors.lastname: Sakolsky
authors.forename: Boris
authors.initials: B
authors.lastname: Birmaher
mesh_terms: D000293:Adolescent; D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002648:Child; D003865:Major Depressive Disorder / Q000188:drug therapy*; D002658:Developmental Disabilities / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D057915:Drug Substitution; D019317:Evidence-Based Medicine; D006801:Humans; D008134:Long-Term Care; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D059020:Suicidal Ideation; D013405:Suicide; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors